Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiFL: Rifaximin in Fatty Liver Disease
2010-021515-17Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rifaximin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Imperial College London. Primary endpoint: Change in serum alanine aminotransferase level. Started Oct 2010; status: terminated.
02
Drugs
rifaximin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2010-021515-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021515-17.